iNKT cells can be activated by direct interaction with tumor cells: CD1d+ tumor cells present endogenous glycolipids via CD1d which is then recognized by the T-cell receptor of iNKT cells leading to perforin/granzyme B or Fas/FasL-mediated cytotoxicity. This evidence concerns the gene GZMB and neoplasm.